Team Spirit! Always a highlight at SCCT! Thanks Stephan Achenbach for putting this together!

#SCCT2023 #TeamSpirit #AchenbachIsAmazing #DontTryToReadCCTin10Seconds

Strong evidence from UK demonstrating increase utilization of Coronary CTA associated with lower CV mortality after the NICE guidelines recommended CCTA as a first line strategy for chest pain patients #SCCT2023

Great panel discussing the implementation, pitfalls and future of AI in Cardiac CT Heart_SCCT Dr Andrew D. Choi Maros Ferencik Marly van Assen Tessa S. Cook MD PhD CIIP FSIIM FCPP Brian with the Good Dictations #SCCT2023

NASCI is a proud co-sponsor of the updated CAD-RADS 2.0!

Read all about it here: sciencedirect.com/science/articl…

Heart_SCCT American College of Radiology American College of Cardiology Eric Williamson Ricardo C. Cury, MD Suhny Abbara MD Gregory Kicska Geoff Rubin MD MBA Stephan Achenbach Ron Blankstein Dr Andrew D. Choi Brian with the Good Dictations Carole Dennie

VIDEO: Top 6 takeaways from the Society of Cardiovascular CT 2022 meeting #SCCT 2022 #SCCT #CCTA #yesCCT #cardiotwitter #radiology #CVimaging #AI
ow.ly/gTpY50K1aWq

Cardiac CT is taking off! Fasten your seatbelts! #SCCT2022 #YesCCT

Great talk by Dr Ricardo Cury on CAD RADS v2
Essential Pearls
💥 Standardized reporting system for CCTA to
improve communication to referring physicians
💥CAD-RADS has been shown to accurately predict
MACE with better performance than other traditional
scores
#YesCCT #SCCT2022

Thank you Khurram for your great partnership!

Ricardo C. Cury, MD well deserved recognition by Heart_SCCT #SCCT2022 for his tremendous contribution towards the field… generously contribution Stephan Achenbach Jack Ziffer Tom Brady ( mentor of mentors)
Congrats my friend!!
Maros Ferencik Michael D. Shapiro Ron Blankstein Brian with the Good Dictations

Amazing honor! #SCCT2022

SCCT growing strong! Amazing how the field is prospering even through the pandemic. Greater than 20% membership growth. #SCCT2022 #YesCCT

Tremendous work from 22 leaders in the field in the updated CAD-RADS 2.0 reporting system for CCTA considering recent clinical trials and increasing data supporting the prognostic relevance of plaque burden and physiologic assessment by Cardiac CT #PlaqueMatters #CTIschemia

Thank you for your tenacity Khurram Nasir It all started in a lunch table at a Cuban restaurant 7 years ago. Miguel Cainzos-Achirica was a powerhouse in the analytics and putting the results together. We are just getting started! Jack Andrew Ziffer @drjbone1 innovative leadership! Baptist Health

Miami Heart Study Baptist Health main results is officially published. Game changer population health study in asymptomatic patients using CCTA demonstrating 49% with presence of plaque, 6% with severe stenosis and 7% with at least one high-risk plaque jacc.org/doi/abs/10.101…

I am honored with this important recognition! It has been a privilege to serve SCCT, the field of Cardiac CT and to have impacted patients at scale. I am eternally grateful to my family, mentors, fellows, friends and colleagues who made this possible!

Radiology Partners+Microsoft!

'In our path for Healthcare Cloud, Digital Transformation, Advanced Data Analytics and AI with the goal to empower our #radiologists to deliver more value to our patients, referring clinicians and hospital partners.' -Ricardo C. Cury, MD, ACMO, Data Strategy

Dr Bamba Gaye presenting in 'Cardiovascular Health After 10 Years: What Have We Learned and What is the Future?'
Young CVD prevention- starts early, with lifestyle, never too early Healthy Lifestyle need to start young
Its also never too late for prevention
#AHA21 #CVDPrevention

Miami Heart Study presented at AHA - Population Health Study demonstrating detection of silent atherosclerotic disease in 49% asymptomatic patients and detection of severe stenosis in 5%. We can do better in CV prevention! #AHA21 #MiHeart #CVDPrevention #CCTA

2021 #CPGuideline algorithms-
❤️Acute CP with suspected ACS-->risk stratify--> intermediate risk with no known CAD-> both Stress testing (>65, higher likelihood of obstructive CAD) or #YesCCT (<65, lower likelihood) recommended (Class 1)a/CDP. Add on testing is 2a.